Biomerica Advances IBS Treatment With InFoods Product, Expands Physician Network Nationwide
Biomerica Advances IBS Treatment With InFoods Product, Expands Physician Network Nationwide
Biomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products is pleased to announce advancements in the roll out of the inFoods IBS product.
全球先进医疗产品提供商Biomerica, Inc.（纳斯达克股票代码：BMRA）（“公司”）很高兴地宣布InFoods IBS产品的推出取得了进展。
Expansion Into New Offices and Physician Engagement:
Biomerica has expanded its reach with adoption by new offices in targeted regions, including the Southeast, Northeast and Midwest. The Company's new salesforce has activated over 30 new Gastrointestinal (GI) physician groups, each with multiple GI physicians, and these new practices have begun recommending the Company's revolutionary inFoods IBS Product to their IBS patients. Furthermore, the average increase in the number of physicians prescribing inFoods more than doubled each quarter over the past 12 months, reflecting growing adoption and trust within the GI medical community.
扩展到新办公室和医生参与：
Biomerica扩大了业务范围，在目标地区（包括东南部、东北部和中西部）采用了新的办事处。该公司的新销售队伍已经启动了30多个新的胃肠道（GI）医生小组，每个小组都有多名胃肠道医生，这些新诊所已开始向他们的肠易激综合征患者推荐该公司革命性的InFoods IBS产品。此外，在过去的12个月中，开InFoods处方的医生人数平均每季度增长一倍以上，这反映了胃肠道医学界的采用率和信任度的提高。
The Company is also in discussions with large non-GI physician groups for utilization of the inFoods IBS test. This advances the strategic effort to expand to non-GI physicians to provide cutting-edge non-pharmaceutical care options for individuals grappling with chronic IBS conditions.
该公司还在与大型非胃肠道医生团体讨论使用InFoods肠易激综合征测试的问题。这推动了向非胃肠易激综合征医生扩展的战略努力，为患有慢性肠易激综合征疾病的个人提供尖端的非药物护理选择。
This continued expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica's influence in providing innovative solutions for irritable bowel syndrome (IBS) while positioning the Company for product revenue growth over the coming quarters.
这种持续扩张表明，InFoods IBS测试在医学界越来越受到认可和采用，扩大了Biomerica在为肠易激综合症（IBS）提供创新解决方案方面的影响力，同时为公司未来几个季度的产品收入增长做好了准备。